It has been reported that KLHDC8A overexpression in human gliomas that become resistant to epidermal growth factor receptor (EGFR) silencing (a commonly used anticancer therapeutic approach), allows tumours to maintain aggressiveness through an unknown EGFR-independent pathway (39). This evidence concerns the gene KLHDC8A and central nervous system cancer.